Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2021 Feb 18;48(10):3260–3267. doi: 10.1007/s00259-021-05236-z

Fig. 1.

Fig. 1

A 42 year-old woman with P-NET G2 with multiple liver metastases, treated with 5.5 GBq of Lu-PRRT in 5 cycles associated with capecitabine 500 mg x 3/die. (A) Baseline FDG PET/CT (A, volumetric; A1, fused transaxial; A2, CT images) before starting the combined treatment. (B) Baseline 68Ga-DOTATOC PET/CT (B, volumetric; B1, fused transaxial; B2, CT images) showing intense uptake (Krenning grade 4) in the liver metastases. (C) 68Ga-DOTATOC PET/CT performed 5 months after the end of combination treatment (C, volumetric; C1, fused transaxial, C2, CT images) shows nearly resolved avidity in the liver lesions.